Skip to contentH
Halozyme Therapeutics, Inc.
H
HALOHalozyme Therapeutics, Inc. Q2 2014 · 10-Q
Revenue$18.39M$18.39M+27.2% vs Q2 2013 Net Income-$16.27M-$16.27MN/M vs Q2 2013 EPS Diluted-$0.13-$0.13N/M vs Q2 2013 Gross Profit$3,570,000+96.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
Operating Cash Flowderived-$15,766,000N/M Free Cash Flowderived-$16,116,000N/M Margins · derivedGross margin19.4%+6.9 pt vs Q2 2013
Operating margin-81.3%+71.8 pt vs Q2 2013
Net margin-88.5%+70.0 pt vs Q2 2013
ended Jun 30, 2014 · filed Aug 11, 2014 · 42 d after period end